ClinVar Miner

Submissions for variant NM_000352.6(ABCC8):c.4353G>A (p.Trp1451Ter)

dbSNP: rs1057516404
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000409836 SCV000485603 likely pathogenic Hyperinsulinemic hypoglycemia, familial, 1 2016-01-12 criteria provided, single submitter clinical testing
Invitae RCV001380090 SCV001578035 pathogenic not provided 2020-12-20 criteria provided, single submitter clinical testing This variant is not present in population databases (ExAC no frequency). For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with ABCC8-related conditions. ClinVar contains an entry for this variant (Variation ID: 370329). This sequence change creates a premature translational stop signal (p.Trp1451*) in the ABCC8 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ABCC8 are known to be pathogenic (PMID: 20685672, 23345197).
Genetic Services Laboratory, University of Chicago RCV001380090 SCV002065880 pathogenic not provided 2021-09-23 criteria provided, single submitter clinical testing
Clinical Genomics, Uppaluri K&H Personalized Medicine Clinic RCV002244843 SCV002513323 uncertain significance Maturity onset diabetes mellitus in young criteria provided, single submitter research Mutations in ABCC8 gene are associated with both neonatal diabetes mellitus as well as MODY. Patients with this mutation may have a better response to sulfonylureas. However, no sufficient evidence is found to ascertain the role of this particular variant ( rs1057516404) in MODY yet.
Clinical Genomics, Uppaluri K&H Personalized Medicine Clinic RCV002244844 SCV002513324 uncertain significance Transitory neonatal diabetes mellitus criteria provided, single submitter research Mutations in ABCC8 gene are associated with both neonatal diabetes mellitus as well as MODY. Patients with this mutation may have a better response to sulfonylureas. However, no sufficient evidence is found to ascertain the role of this particular variant (rs1057516404 ) in neonatal diabetes yet.
Baylor Genetics RCV003475943 SCV004203245 likely pathogenic Type 2 diabetes mellitus 2023-04-21 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.